Attacking angiogenesis has recently moved to the front lines of the fight against cancer (1) (2) (3) 
promiscuous ECM receptor, which recognizes several ligands found in subendothelial and stromal ECM, including fibronectin, vitronectin, thrombospondin, and fibrinogen. Brooks et al. (6) reported previously that endothelial cells express avf3 strongly in periods of angiogenesis, for example, during development and wound healing, and in response to angiogenic factors. However human metastatic breast tumor cell line) were injected intradermally into full thickness human neonatal foreskin transplanted onto SCID mice (7) . When evaluated after 5 wk, the MCF-7PB cells formed solid tumors that contained an extensive network of human blood vessels. However, systemic introduction of the LM609 anti-av/3 monoclonal antibody 2 wk after tumor cell injection, greatly reduced tumor size at 5 wk: many anti-av,83 treated animals had no palpable tumors at all. Those tumors which did form were significantly smaller than control antibody-treated tumors, contained many fewer blood vessels, and had smooth margins. In contrast the margins of the larger control tumors showed evidence of stromal invasion, and tumor cells were frequently detected within the tumor-associated vessel network. Thus, the breast tumors that did form in the anti-av,63-treated animals did not display the angiogenic or invasive phenotypes thought to favor subsequent metastasis.
Although no data are shown, the authors report a similar inhibition of angiogenesis by LM609 after introduction of melanoma cells into the human skin/SCID model. 
